Literature DB >> 19962820

Arsenic trioxide-mediated Notch pathway inhibition depletes the cancer stem-like cell population in gliomas.

Yunbo Zhen1, Shiguang Zhao, Qiang Li, Yi Li, Keiji Kawamoto.   

Abstract

Cancer stem-like cells (CSLCs) are potential targets for treatment of glioblastoma multiforme (GBM) due to their role in tumorigenesis and recurrence. In this study, we investigated the inhibitory effect of arsenic trioxide (As(2)O(3)) on CSLCs of GBM in human glioma cell lines (U87MG, U251MG and U373MG) in vivo and in vitro. Immunofluorescence staining and flow cytometry revealed that the percentage of Nestin-positive cells in the aforementioned cell lines was diminished by 12%, 14% and 7%, respectively, after treatment with 2 microM As(2)O(3). Furthermore, we used soft-agar in U87MG and tumor xenografts in nude mice to demonstrate the ability of As(2)O(3) to inhibit the formation of tumor in the three cell lines. These results indicate the negative regulation of CSLCs by As(2)O(3). In addition, a Western blot analysis revealed decreased levels of Notch1 and Hes1 proteins due to As(2)O(3) treatment. We conclude that As(2)O(3) has a remarkable inhibitory effect on CSLCs in glioma cell lines in vivo and in vitro; in addition, we determined that the mechanism of CSLC inhibition involves the deregulation of Notch activation. Copyright (c) 2009 Elsevier Ireland Ltd.All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19962820     DOI: 10.1016/j.canlet.2009.11.005

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  26 in total

1.  Inhibition of Notch signaling alters the phenotype of orthotopic tumors formed from glioblastoma multiforme neurosphere cells but does not hamper intracranial tumor growth regardless of endogene Notch pathway signature.

Authors:  Karina Kristoffersen; Mette Kjølhede Nedergaard; Mette Villingshøj; Rehannah Borup; Helle Broholm; Andreas Kjær; Hans Skovgaard Poulsen; Marie-Thérése Stockhausen
Journal:  Cancer Biol Ther       Date:  2014-04-22       Impact factor: 4.742

2.  Arsenic trioxide inhibits cancer stem-like cells via down-regulation of Gli1 in lung cancer.

Authors:  Ke-Jie Chang; Meng-Hang Yang; Jin-Cheng Zheng; Bing Li; Wei Nie
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

3.  The impact of arsenic trioxide and all-trans retinoic acid on p53 R273H-codon mutant glioblastoma.

Authors:  Michael Karsy; Ladislau Albert; Raj Murali; Meena Jhanwar-Uniyal
Journal:  Tumour Biol       Date:  2014-01-08

4.  Xiaotan Sanjie decoction attenuates tumor angiogenesis by manipulating Notch-1-regulated proliferation of gastric cancer stem-like cells.

Authors:  Bing Yan; Long Liu; Ying Zhao; Li-Juan Xiu; Da-Zhi Sun; Xuan Liu; Ye Lu; Jun Shi; Yin-Cheng Zhang; Yong-Jin Li; Xiao-Wei Wang; Yu-Qi Zhou; Shou-Han Feng; Can Lv; Pin-Kang Wei; Zhi-Feng Qin
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

5.  Phase I study of arsenic trioxide and temozolomide in combination with radiation therapy in patients with malignant gliomas.

Authors:  Sean A Grimm; Maryanne Marymont; James P Chandler; Kenji Muro; Steven B Newman; Robert M Levy; Borko Jovanovic; Katie McCarthy; Jeffrey J Raizer
Journal:  J Neurooncol       Date:  2012-08-09       Impact factor: 4.130

6.  Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids.

Authors:  Jesper Kolenda; Stine Skov Jensen; Charlotte Aaberg-Jessen; Karina Christensen; Claus Andersen; Nils Brünner; Bjarne Winther Kristensen
Journal:  J Neurooncol       Date:  2010-09-11       Impact factor: 4.130

Review 7.  From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia.

Authors:  Sai-Juan Chen; Guang-Biao Zhou; Xiao-Wei Zhang; Jian-Hua Mao; Hugues de Thé; Zhu Chen
Journal:  Blood       Date:  2011-03-21       Impact factor: 22.113

8.  Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma.

Authors:  Danka Cholujova; Zdenka Bujnakova; Erika Dutkova; Teru Hideshima; Richard W Groen; Constantine S Mitsiades; Paul G Richardson; David M Dorfman; Peter Balaz; Kenneth C Anderson; Jana Jakubikova
Journal:  Br J Haematol       Date:  2017-10-19       Impact factor: 6.998

9.  ASYMMETRIC CELL DIVISION: IMPLICATIONS FOR GLIOMA DEVELOPMENT AND TREATMENT.

Authors:  Kate Marie Lewis; Claudia Petritsch
Journal:  Transl Neurosci       Date:  2013-12       Impact factor: 1.757

10.  A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas.

Authors:  Priya Kumthekar; Sean Grimm; James Chandler; Minesh Mehta; Maryanne Marymont; Robert Levy; Kenji Muro; Irene Helenowski; Katie McCarthy; Leanne Fountas; Jeffrey Raizer
Journal:  J Neurooncol       Date:  2017-05-16       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.